TENAX THERAPEUTICS INC
TENXNASDAQTrading Snapshot
- Day Range
- $1.61 – $1.63
- 52-Week Range
- $1.31 – $19.40
- Volume
- $1.72B
- Avg Volume
- $2.12B
- Shares Outstanding
- 26.5M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $5,942
- Last Q Revenue
- $1,531
- P/E Ratio
- —
- P/S Ratio
- 10202.4x
- EPS (TTM)
- $-1.40
- Dividend Yield
- —
Why Investors Own TENX
- ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About TENAX THERAPEUTICS INC
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow
2026-08-11. The following slide deck was published by Tenax Therapeutics, Inc.
William Blair Downgrades Tenax Therapeutics to Market Perform
William Blair analyst Matt Phipps downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to Market Perform.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release, H1 earnings